A Study to Evaluate the Efficacy of Botulinum Toxin in Patients With Hidradenitis Suppurativa

ConditionHidradenitis Suppurativa (HS)

Trial statusNot yet recruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age13-75

SponsorUniversity of Massachusetts, Worcester

About this trial

This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease hidradenitis suppurativa (HS). In this study, the investigators will extend data from a 12-week pilot study to rigorously test the hypothesis that botulinum toxin (BoNT) therapy reduces disease severity and relieves HS pain symptoms..

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

Botulinum Toxin A (Allergan, Inc, Irvine CA)
Placebo

Treatment groups

40 Participants

are divided into 2 treatment groups

Sponsors and collaborators

University of Massachusetts, Worcester

Lead sponsor

Emory University

Collaborator

Source ClinicalTrials.gov